Notice for osimertinib [as mesilate] (AstraZeneca Pty Ltd)
Active ingredients
osimertinib [as mesilate]
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the adjuvant treatment after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations
Therapeutic area
Oncology